Evidence map›Paper›PMID 36077495›Full record

ReviewInternational journal of molecular sciences2022

The Pleiotropy of

Parinaz Nasri Nasrabadi, Danick Martin, Ehsan Gharib, Gilles A Robichaud

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Uncovering cancer dependencies in peptide-interacting protein pockets.bioRxiv : the preprint server for biology · 2026
    Article
  9. Article
  10. Article
  11. [Research progress on copy number alterations in pediatric B-cell acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  12. PAX Family, Master Regulator in Cancer.Diagnostics (Basel, Switzerland) · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. The Role of the PAX Genes in Renal Cell Carcinoma.International journal of molecular sciences · 2024
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Parinaz Nasri NasrabadiDépartement de Chimie et Biochimie, Université de Moncton, Moncton, NB E1A 3E9, Canada.
Danick MartinDépartement de Chimie et Biochimie, Université de Moncton, Moncton, NB E1A 3E9, Canada.
Ehsan GharibDépartement de Chimie et Biochimie, Université de Moncton, Moncton, NB E1A 3E9, Canada.
Gilles A RobichaudDépartement de Chimie et Biochimie, Université de Moncton, Moncton, NB E1A 3E9, Canada.ORCID 0000-0002-5782-7899

Funding

Beatrice Hunter Cancer Research Institute DM-2020Canadian Cancer Society CHA-22Leukemia & Lymphoma Society of Canada OG2019Mitacs AccelerateMitacs ElevateNew Brunswick Health Research Foundation OG-NBHRF/LLSC-2020New Brunswick Innovation Foundation RAI-2022
6 · The paper itself

Abstract

PAX5, a member of the Paired Box (PAX) transcription factor family, is an essential factor for B-lineage identity during lymphoid differentiation. Mechanistically, PAX5 controls gene expression profiles, which are pivotal to cellular processes such as viability, proliferation, and differentiation. Given its crucial function in B-cell development,

Indexed as

PAX5 Transcription FactorProteinsCell DifferentiationHematopoiesisPAX5 Transcription FactorProteinsB-cellbreast cancerBSAPcancerdifferentiationleukemialymphomamaturationoncogenePAX5transcription factortumor suppressor

Identifiers

PMID36077495
PMCPMC9456430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.